Castle Brands Inc. (AMEX:ROX) recently reported financial results for the three months ended June 30, 2010. In the fiscal 2011 first quarter, the Company had net sales of $6.1 million, a 4.4% increase from the prior year period. Net loss from operations was $1.7 million for the three months ended June 30, 2010, an improvement of 11.3% from $2.0 million for the comparable fiscal 2010 period.
Castle Brands is a developer and international marketer of premium and super premium beverage alcohol brands including: Gosling’s Rum, Jefferson’sTM, Jefferson’s Presidential SelectTM and Jefferson’s Reserve Bourbon, Boru Vodka, Pallini LimoncelloTM, RaspicelloTM and PeachcelloTM, Knappogue Castle Whiskey, Clontarf Irish Whiskey, Betts & SchollTM wines, Celtic Crossing Liqueur, Brady’s Irish Cream, A. De Fussigny Cognacs, Travis Hasse’s Original Liqueurs and TierrasTM tequila.
CCA Industries Inc. (AMEX:CAW) recently reported its earnings for the second quarter ended May 31, 2010. For the three month period ended May 31, 2010, the Company had total revenues of $14,855,217, a net loss of $(910,589) and a fully diluted loss per share of $(0.13) as compared to total revenues of $14,748,329, net income of $694,136 and fully diluted earnings per share of $0.10 for the three month period ended May 31, 2009. The net loss was as a result of the Company recording a charge against income of $2,067,407 for the settlement of the “Wally vs. CCA” advertising litigation.
CCA Industries, Inc. engages in manufacturing and selling health and beauty aid products primarily in the United States and Canada.
Proteonomix, Inc. (PROT.OB) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.
PROT recently reported further developments with its Joint Venture Company, XGEN Medical LLC (”XGen”) towards implementing operations in the United Arab Emirates.
Proteonomix is the majority shareholder in XGen with the balance held by an anonymous investor group. Proteonomix personnel were on the ground in the U.A.E. over the past weeks to work together with the Investor Group through the start up phase.
This wholly owned subsidiary will be the vehicle to conduct business in the GCC countries. XGen has filed the corporate papers and has established banking relations with a local bank both for receipt of the initial investment of $5 million and towards further financing expanded services in the region.
It was further reported that XGen has expanded its talks within the region beyond a license for manufacture of and treatment with Proteonomix cellular material. Discussions are now further encompassing both the construction of XGen’s own manufacturing and treatment facility within the U.A.E. and on funding phased trials for one or more of PROT proprietary cellular materials for treatment of disease.
Additionally, the agreement calls for XGen, the joint venture, to market and distribute Proteoderm, including the Matrix NC-138 anti-aging products .
Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, http://www.proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products.
For more information about this company please visit http://www.proteonomix.com
CEL-SCI Corp. (AMEX:CVM) announced today it has received approval from the Ethical Council Affiliated with the Ministry of Healthcare and Social Development of the Russian Federation (“Ethical Council”) for the Phase III clinical trial of Multikine, the Company’s flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. CEL-SCI expects to have three clinical centers in Russia, out of an expected forty-eight clinical centers world-wide. Head and neck cancer is a major cancer in Russia.
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine. In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients’ overall survival by 33 percent at a median of three and a half years following surgery.
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup
PLEASE BE SURE TO VISIT CRWESELECT.NING.COM
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB).